is an oncogenic virus that infects more than 90% of the world's population 1 . EBV predominantly infects human B cells and epithelial cells, which is initiated by fusion of the viral envelope with a host cellular membrane 2 . The mechanism of EBV entry into B cells has been well characterized 3 . However, the mechanism for epithelial cell entry remains elusive. Here, we show that the integrins αvβ5, αvβ6 and αvβ8 do not function as entry and fusion receptors for epithelial cells, whereas Ephrin receptor tyrosine kinase A2 (EphA2) functions well for both. EphA2 overexpression significantly increased EBV infection of HEK293 cells. Using a virus-free cell-cell fusion assay, we found that EphA2 dramatically promoted EBV but not herpes simplex virus (HSV) fusion with HEK293 cells. EphA2 silencing using small hairpin RNA (shRNA) or knockout by CRISPR-Cas9 blocked fusion with epithelial cells. This inhibitory effect was rescued by the expression of EphA2. Antibody against EphA2 blocked epithelial cell infection. Using label-free surface plasmon resonance binding studies, we confirmed that EphA2 but not EphA4 specifically bound to EBV gHgL and this interaction is through the EphA2 extracellular domain (ECD). The discovery of EphA2 as an EBV epithelial cell receptor has important implications for EBV pathogenesis and may uncover new potential targets that can be used for the development of novel intervention strategies.
mechanism of epithelial cell infection. The B cell receptor HLA-DR was identified to bind to gp42 by a gp42 ligand binding screen in 1996 (ref. 7 ). In 1997, it was found that HLA-DR functions as a cofactor for infection of B lymphocytes 8 . Since then, we have worked extensively on EBV entry, determining the structures of unbound gp42, the gp42:HLA complex, the gHgL complex and gB in the postfusion form [9] [10] [11] [12] . Recently, we assembled and analysed the reconstituted B cell entry complex composed of gHgL, gp42 and HLA class II, and the crystal structure of the gHgL/gp42 complex bound to an anti-gHgL antibody (E1D1), providing an overall structural foundation for understanding EBV host-cell tropism 3, 13 .
To characterize the EBV epithelial cell entry complex, in a manner similar to that carried out for the B cell entry complex 3 , we first wanted to verify the receptor used for epithelial cell entry. We chose the AGS cell line (a human gastric adenocarcinoma cell line), which has been used extensively as a model of EBV epithelial cell entry, and human embryonic kidney 293 (HEK293) cells, which we used in our cell-based fusion assay. Previous studies have indicated that the integrins (αvβ5, αvβ6 and αvβ8, but not αvβ3) function as receptors for epithelial cell entry 14, 15 . It was also found that blocking antibodies to integrins and siRNA targeting of integrin αv did not completely abolish epithelial cell fusion or infection 14 . In addition, three anti-gHgL monoclonal antibodies (CL40, CL59 and E1D1) targeting different epitopes can all inhibit epithelial cell infection, indicating that multiple regions on gHgL may participate in EBV infection 16 . To determine if integrins are the primary epithelial cell receptor, we chose to knock out the integrin αv gene using the CRISPR-Cas9 system in HEK293-T14 cells. Integrins αvβ5, αvβ6 and αvβ8 are heterodimeric complexes composed of the αv subunit and a β subunit. The crystal structure of EBV gHgL with an exposed KGD motif (RGD motif mimic) within gH domain II (D-II) suggested it might bind to the αv subunit of the heterodimeric integrins reported to function as entry receptors 14, 17 . By knocking out αv, we would block expression of the integrins previously shown to mediate EBV entry into epithelial cells. Integrin αv knockout clonal cell lines were readily obtained and were first analysed by flow cytometry, verifying the absence of αv (Fig. 1a ). We next used our cell-cell fusion assay to monitor syncytia formation. We found that cells lacking integrin αv still fused with Chinese hamster ovary (CHO-K1) cells that expressed gHgL and gB ( Fig. 1b) , indicating that αvβ5, αvβ6 and αvβ8 integrins are not the primary receptor(s) in HEK293 cells.
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previously that EBV containing only gB and gHgL, but lacking gp42, is unable to infect B cells 18 . In addition, previous data have shown that CHO-K1 cells that express gHgL and gB, but not gp42, can fuse with HEK293 cells but not B cells, further indicating that B cells do not express epithelial cell receptors 19 . To identify candidate epithelial cell receptors, we screened B cell and HEK293 cell RNA-seq data sets. In our analysis, we screened the data sets such that the mRNA of HEK293 candidates versus the mRNA of B cell candidates was tenfold greater and that the HEK293 cell gene reads were over the 5 FPKM (fragment per kilobase per million mapped reads) threshold as the lower boundary for reliable detection of gene expression. From this analysis, we selected 2,039 genes out of 18,400 genes that were compared. We then selected membrane proteins and excluded genes that had B cell reads of more than 5 FPKM. This analysis resulted in 245 genes ( Supplementary Table 1 ). To further reduce the number of potential genes, we used RNA-seq data from AGS cells. AGS cells are a human gastric adenocarcinoma and have been used extensively as a model of EBV epithelial cell entry 14, 20 . This cell line forms larger syncytia and cells are more readily infected than HEK293 cells (data not shown), and gastric epithelial cells are a target of EBV infection 21 . When comparing the expression of the 245 genes (EphA2 ranked no. 14, fold difference 864, Supplementary  Table 1 ) identified in the HEK293 cell RNA-seq data and selecting only those genes that are expressed twofold greater in AGS cells, we identified 39 genes. After ranking these genes according to the ratio of AGS to B cell expression from high to low, EphA2 was ranked as the no. 1 candidate ( Fig. 1c and Supplementary Table 2 ). Interestingly, if we first compared AGS cells with B cells using similar parameters (B cell expression <5 FPKM, AGS cell expression >5 FPKM, AGS cell/B cell >10, membrane protein), this resulted in 278 genes ( Supplementary Table 3 ) and EphA2 was ranked no. 9 (fold difference of 6,798). If we selected only those genes that are expressed twofold greater in AGS cells, we identified 65 genes (Supplementary Fig. 1 and Supplementary Table 4 ). If we compared the first 15 genes of membrane proteins selected out by two methods (Supplementary Tables 1 and 3 ), EphA2 and PAQR5 are the only genes shared by the two methods. EphA2 is also the receptor for Kaposi's sarcoma-associated herpesvirus (KSHV), another human gammaherpesvirus 22, 23 . EphA2 belongs to the ephrin receptor family, which is the largest family of tyrosine kinase receptors. The function of EphA2 includes cell migration, adhesion, proliferation, and differentiation. Eph receptors are divided into two classes, A and B, based upon sequence similarity and ligand affinity 24 . As we had found that EphA2 had the greatest differential expression profile among B cells, HEK293 cells and AGS cells ( Fig. 1c ), we wanted to verify its expression using quantitative RT-PCR (reverse transcription-polymerase chain reaction) and flow cytometry. As expected, we confirmed that Daudi B cells do not express EphA2 ( Fig. 1d ) and the expression level of EphA2 in AGS cells is about tenfold more than that of HEK293 cells ( Fig. 1d,e ). It has been shown that EphA2 is expressed on tongue mucosa and in the salivary gland 25, 26 . EphA2 has also been shown to be expressed on normal gastric mucosa, and EphA2 expression is upregulated in the carcinogenesis of gastric mucosa epithelial cells 27, 28 .
To determine whether EphA2 serves as a receptor for EBV infection of epithelial cells, we first transiently transfected control vector, EphA2 or EphA4 into HEK293 cells to see if EphA2 increases EBV infection or fusion. We used expression vectors for EphA2 or EphA4. Over-expression of EphA2 increased the cell surface expression of EphA2 by about tenfold in HEK293 cells (Fig. 2b) . These cells were also infected with EBfaV-GFP (recombinant EBV reporter virus expressing green fluorescent protein (GFP) 29 ), with the resulting infection increasing the detection of green cells in control transfected HEK293 cells ( Fig. 2a,b ). The number of GFP-expressing cells also increased in EphA2 but not EphA4 transfected HEK293 cells ( Fig. 2b ). Flow cytometry data and quantification confirmed that EphA2 but not EphA4 increased EBV infection in HEK293 cells ( Fig. 2c ). Furthermore, EphA2 expression in HEK293 cells led to significantly increased fusion with CHO-K1 cells expressing the EBV glycoproteins gB and gHgL, but not HSV glycoproteins. EphA4 over-expression had no effect on fusion of either EBV or HSV ( Fig. 2d ).
To further confirm that EphA2 can serve as a cellular receptor for EBV infection, we knocked out EphA2 using the CRISPR-Cas9 system. Following knockout, EphA2 cell surface expression was decreased to the level of the negative control ( Fig. 3a ). Both EBV fusion and infection were dramatically decreased in EphA2 knockout cells ( Fig. 3b-e ). This marked reduction was rescued by over-expression of EphA2 ( Fig. 3b-e ) but not EphA4. HSV fusion activity was not affected in all the cells tested, indicating the specificity of EphA2 as an EBV receptor ( Fig. 3b ). We performed additional control experiments using shRNA to knock down EphA2 in HEK293-T14 and AGS cells and found a similar reduction in fusion ( Supplementary Figs. 2-3 ). As a further confirmation of EphA2 EBV receptor activity, we found that an antibody against EphA2 but not EphA4 can block the infection of nasopharyngeal carcinoma cell line Detroit 562 ( Supplementary Fig. 4a ). Interestingly, murine EphA2, which shares 93% identity with human EphA2, can also increase fusion and infection with EBV ( Supplementary Fig. 4b,c ). When we mixed the EphA2 knockout (KO) cells and wild-type (WT) cells at a 1:1 ratio, the infection ability of EphA2 KO cells by EBV was further decreased ( Supplementary Fig. 5a ,b), indicating that there may be another low-affinity receptor that is unable to compete with the EphA2 when EphA2 is present.
EphA2 is also the receptor for Kaposi's sarcoma-associated herpesvirus (KSHV), another human gammaherpesvirus 22, 23 . Previous data have shown that KSHV gHgL binds to the ligand-binding domain of EphA2 (ref. 30 ). To examine whether the EphA2 functions through the ligand-binding domain in EBV fusion, we swapped the ligand-binding domains of EphA2 and EphA4 to generate EphA2A4 or EphA4A2 chimaeras. We found that replacing the EphA4 ligandbinding domain with the EphA2 ligand-binding domain (EphA2A4 chimaera) increased fusion activity threefold, suggesting that, like KSHV, EBV gHgL also binds the ligand-binding domain of EphA2 ( Fig. 4a ). To examine whether EphA2 kinase activity is important for fusion, we also tested three EphA2 kinase dead mutants that were mutated in the EphA2 kinase domain and found that the kinase activity of EphA2 is not important for EBV fusion (Fig. 4b ).
It has been shown that the kinase activity of EphA2 is important for KSHV infection 23 . Depending upon cell type, EBV can enter cells by fusion at the plasma membrane (epithelial cells) or fusion with an endocytic membrane after endocytosis (B cells) 2 . KSHV enters human B cells, fibroblast, epithelial and endothelial cells by endocytosis, and EphA2 regulates clathrin-mediated KSHV endocytosis 31, 32 . The different route of entry may explain the differing requirements of EphA2 kinase function in EBV and KSHV infection. To explore the region of gHgL that binds EphA2, we took advantage of previous observations indicating that the gHgL domain for gp42 binding and epithelial cell binding overlap 17, 33 . When an expression vector expressing gp42 or purified soluble gp42 is included in our fusion assay, the level of fusion is dramatically reduced (Fig. 4c ), indicating that gp42 binding to gHgL blocks EphA2-mediated membrane fusion, in line with previous observations. To further confirm the direct binding of the EphA2-ECD and EBV gHgL, we used labelfree surface plasmon resonance (SPR) binding studies and found that purified EBV gHgL bound to EphA2 with a dissociation constant (K D ) of 5 μM in three independently repeated binding kinetics experiments, but EBV gHgL did not bind to EphA4 under the same conditions (Fig. 4d ,e and Supplementary Table 5 ). The 200 nM concentration of EBV gHgL was injected in duplicate each time, with randomized order of injections, with the second 200 nM injection Letters Nature Microbiology occurring after the 1.8 µM EBV gHgL injection to serve as internal control. Figure 4d shows that both injections of the same concentration (200 nM) overlap each other. Previous data from a flow cytometry binding assay showed that KSHV gHgL can bind tightly with EphA2 in particular, but only weakly with other ephrin receptors including EphA4 (ref. 34 ). This suggests that gammaherpesviruses share a common entry receptor. Taken together, we identify EphA2 as an important epithelial cell entry receptor for EBV infection. This result provides important insight into the mechanism EBV uses to infect epithelial cells, and may provide a better understanding of the development of epithelial pathologies and cancers associated with EBV infection, as well as strategies to lessen EBV-associated epithelial cancers. Finally, our studies using bioinformatics to implicate EphA2 as an EBV epithelial receptor highlight the benefit of using readily obtainable sequencing data to aid in the discovery of pathogen receptors. 
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Methods
Cell culture. CHO-K1 cells (ATCC CCL-61 or CRL-9618) were grown in Ham's F-12 medium (Corning) containing 10% heat-inactivated fetal bovine serum complex (FBS) (Corning) and 1% penicillin-streptomycin (100 U penicillin ml −1 , 100 µg streptomycin ml −1 ; Sigma). HEK293 cells (ATCC CRL-1573) or HEK293-T14 cells (HEK293T cells stably expressing T7 RNA polymerase, ATCC CRL-3216) were grown in DMEM with 100 µg ml -1 zeocin (Invitrogen, for HEK293T cells expressing T7 RNA polymerase only), respectively containing 10% heat-inactivated FBS and 1% penicillin-streptomycin. Detroit 562 cells (ATCC CCL138) were grown in MEM medium (Corning) containing 10% heat-inactivated FBS (Corning) and 1% penicillin-streptomycin (100 U penicillin ml −1 , 100 µg streptomycin ml −1 ; Sigma). CHO-K1, HEK293, HEK293T, AGS and Detroit 562 cells were obtained from ATCC and routinely tested for mycoplasma using a LookOut Mycoplasma PCR Detection Kit (Sigma). Cell lines were authenticated by ATCC and not authenticated in our laboratory.
Constructs. The EphA2, EphA2 kinase-dead mutants and EphA4 constructs were a gift from S. Getsios. Construction of the EphA2 and EphA4 chimaeras (EphA2A4 or EphA4A2) was performed using overlapping PCR with the following primers: EphA4A2 HindIII F: 5-TTAAGCTTATGGCTGGGATTTTCTATTTC-3, EphA4A2 
Generation of integrin and EphA2 KO cells.
For integrin αv KO cells, 5 × 10 5 HEK293-T14 cells per well in a six-well plate were transfected with 3 µg integrin αv sgRNA/Cas9 or sgRNA/Cas9 control plasmids. After 48 h, the cells were dissociated and resuspended in 10 ml 10% FBS-DMEM and passed through a 100 µm cell strainer. The cells were counted and seeded at a concentration of 0.5 cells per 100 μl. After 3 weeks, single-cell colonies were picked and expanded for functional assays. Knockout of integrin αv in these cells was confirmed by flow cytometry. For EphA2 KO cells, Cas9-expressing stable HEK293-T14 cells were established by infecting with lentivirus that had Cas9 for 24 h. After 24 h, the cells were changed to fresh medium with 5 μg ml -1 blasticidin for selection. After one week, the cells were colonized and expanded for 2-3 weeks. Cas9 expression in these single-cell colonies was analysed using western blotting against Flag. 2.5 × 10 5 HEK293-T14-Cas9 cells per well in a 12-well plate were infected with lentivirus that had control sgRNA or EphA2 sgRNA. The cells were selected with 2 μg ml -1 puromycin and colonized. After 2-3 weeks of expansion, the knockout of EphA2 was confirmed by flow cytometry.
Generation of EphA2 knockdown cells in HEK and AGS cells.
EphA2 knockdown cells were created by lentiviral transduction of a pLKO.1 vector containing EphA2-specific shRNA (sequence: CCGGCGGACAGACATATAGGATATTCTC GAGAATATCCTATATGTCTGTCCGTTTTT, underlined sequence is the hairpin loop) in HEK 293-T14 and AGS cells. The AGS and HEK293-T14 cells were under puromycin (2.5 μg ml -1 and 2 μg ml -1 , respectively) selection for two weeks, and the surface expression of EphA2 was analysed by flow cytometry before use in fusion experiments.
Fusion assay. The virus-free cell-based fusion assay was performed as described previously 17 . Briefly, CHO-K1 cells grown to ~80% confluency were transiently transfected with T7 luciferase reporter plasmid with a T7 promoter (1.5 µg) and other essential glycoproteins for EBV fusion including gB (0.8 µg), gH (0.5 µg) and gL (0.5 µg), or for HSV fusion including HSV gB (0.8 µg), gH (0.5 µg) gL (0.5 µg) and gD (0.5 µg) by using Lipofectamine 2000 transfection reagent (Invitrogen) in Opti-MEM (Gibco-life Technology). HEK293 cells or HEK293-T14 WT and EphA2 KO cells were transfected with T7 polymerase (1.5 μg) plus 1.5 μg pcDNA 3.1, EphA2 or EphA4 for the fusion assay. At 24 h post-transfection, cells were detached, counted and mixed 1:1 with target cells (HEK293 cells, 2.0 × 10 5 per sample) into a 48-well plate in 0.5 ml Ham's F-12 medium with 10% heat-inactivated FBS. After 24 h, the cells were washed once with PBS and lysed with 50 µl of passive lysis buffer (Promega). Luciferase activity was quantified by transferring 20 µl of lysed cells to a 96-well plate and adding 50 µl of luciferase assay reagent (Promega). Luminescence was measured on a PerkinElmer Victor plate reader.
Cell surface expression. Surface expression of EphA2 or integrin αv was performed by flow cytometry analysis. A total of 1 × 10 6 cells were collected and washed in PBS containing 1% BSA and incubated with 5 μl PE-conjugated EphA2 antibody (Biolegend, SHM16) or PE-conjugated integrin αv (R&D systems, FAB1219P) in 50 μl PBS containing 1% BSA for 30 min at 4 °C. Cells were then washed and diluted in 300 μl PBS containing 1% BSA. Data were acquired using a BD LSR Fortessa instrument and FlowJo software was used for analysis.
EBV infection.
A total of 7.5 × 10 7 ml of cells infected with EBfaV-GFP (recombinant EBV reporter virus expressing GFP 29 ) were grown in 100 ml RPMI with 10% FBS, penicillin-streptomycin and 30 ng ml -1 12-O-tetradecanoylphorbol-13-acetate (TPA) at 37 °C, 5% CO 2 for 4 days. The supernatant was collected by spin down at 1,500 r.p.m. for 10 min, aliquoted in 1 ml and frozen at −80 °C, or was centrifuged at 13,000 r.p.m. for 30 min at 4 °C. The pellets were resuspended in 100 μl of 10% FBS DMEM. A total of 5 × 10 4 HEK293 cells per well were seeded on a 48-well plate and infected on the second day with 100 μl EBV virus in 10% FBS DMEM. For the blocking assay, Detroit 562 cells growing in a transwell were pretreated with anti-EphA2 (2 μg μl -1 , R&D system, AF3035) or anti-EphA4 (2 μg μl -1 , Life Technologies, 371600) for 1 h and infected with EBV virus concentrated from 5 ml supernatant 35 .
Bioinformatics. Sequence Read Archive (SRA) data of RNA-seq for HEK293 (SRR5011298, SRR5011302 and SRR5011303), AGS (SRR2084426, SRR2084600 and SRR2084602) and B cells (SRR5048161, SRR5048160, SRR5048157 and SRR5048158) were downloaded from the SRA database (https://www.ncbi.nlm. nih.gov/sra). The SRA data were transformed into the original FASTQ documents using NCBI SRA Toolkit fastq-dump. The original documents were trimmed using FASTX and aligned to the reference genome using TopHat. Differential expression analysis was performed using Cuffdiff software. The genes encoding membrane proteins that had a tenfold increase in HEK293 cells compared with B cells were chosen as candidates and further filtered according to original reads (>5 FPKM in HEK293 cells and <5 FPKM in B cells). Among the candidate genes from the comparison of B and HEK293 cells, the final top candidate genes were chosen if they had maximum reads in AGS cells. The heatmap was generated using HemI software.
Quantitative RT-PCR. Expression of EphA2 and EphA4 mRNA in HEK293 cells was examined by quantitative RT-PCR (qRT-PCR) analysis, using the following primers: EphA2 F 5-AAGGAAGTGGTACTGCTGGA-3 and R: ACGTTGCACACGGAGTACAT; control GAPDH primers: F: 5-TGGTATCGTGGAAGGACTCATGAC-3, R: 5-ATGCCAGTGAGCTTCCCGTTCAGC-3. Real-time PCR was performed using a StepOnePlus Real-Time PCR System (Applied Biosciences) with iQ SYBR supermix from BioRad. We used a two-step amplification (40 cycles of 95 °C, 15 s; 60 °C, 30 s; followed by melting temperature determination stage) and quantified relative changes in gene expression using the ΔΔCt method according to the manufacturer's instructions (Applied Biosciences).
Cloning, expression and purification of EBV proteins. EBV gH residues 18-679 and EBV gL 22-137 representing the soluble EBV gHgL protein were cloned by Gibson assembly into pTTVH8G expression vector (National Research Council Canada, N R C licence file 11266). Either vascular endothelial growth factor (VEGF) as the signal sequence (SS) as part of the pTTVH8G vector or the native gH or gL SS were used to make four different plasmids (two for EBV gH and two for EBV gL, Supplementary Fig. 6 ). Empty pTTVH8G served as the 'vector' , while pSG5-gH and gL expressing full-length EBV proteins were used as the 'fragment' templates in the Gibson assembly reaction (New England Biolabs). The following different primers were used in the Gibson assembly reaction: (1) EBV gH, VEGF SS resulting in a 8,012 bp plasmid used fragment-forward: 5′-atgccaagtggtcccaggctGCCAGCCTCAGC-3′; fragmentreverse: 5′-gtcgaggtcgggggatctcaGTGTGCTCTTTCTTCATACAGGCCC-3′; vector-forward: 5′-TGTATGAAGAAAGAGCACACtgagatcccccgacctcgac-3′; vector-reverse: 5′-TTAACCTCGCTGAGGCTGGCagcctgggaccact-3′; (2) EBV gH, native SS plasmid resulting in a 7,985 bp plasmids used fragment-forward: 5′-aacggatctctagcgaattcATGCAGTTGCTCTGTGTTTTTTGC-3′; fragmentreverse: 5′-gtcgaggtcgggggatctcaGTGTGCTCTTTCTTCATACAGGCCC-3′; vector-forward: 5′-TGTATGAAGAAAGAGCACACtgagatcccccgacctcgac-3′; vector-reverse: 5′-AAAACACAGAGCAACTGCATgaattcgctagagatccgtttaaact-3′; 
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Pierce Gentle Ag/Ab elution buffer pH 6.6 (Thermo Fisher Scientific) and purified by a final Superdex 200 gel filtration column (GE Life Sciences) in 1× PBS pH 7.4. Gp42 was expressed and purified as previously described 3 .
SPR binding kinetics. The binding kinetics assay to determine on rate (k a ), off rate (k d ) and affinity (K D ) between EBV gHgL and EphA2 or EphA4 was performed using a Bioptix 404pi biosensor instrument (BiOptix, CO). 1× PBS pH 7.4 with 0.05% (vol/vol) Tween-20 was used as the running buffer. EphA2 (R&D systems 3035-A2-100) or EphA4 (R&D systems, 6827-A4-050) (as the 'ligand') were immobilized onto separate channels on a carboxy-methyl dextrose (CMD-200m; BiOptix) biosensor chip by the amine-coupling method using EDC/NHS (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride/N-Hydroxysuccinimide) chemicals (Sigma).Deactivated surface using ethanolamine was used as the reference channel. Sensorgrams with different serial dilutions, that is, the concentration series of EBV gHgL as the mobile analyte, were flown over the ligand and the reference subtracted sensorgram data fit globally to a 1:1 interaction model using GraphPad Prism 7. Kinetic parameters from the model fit are presented in Supplementary Table 5 . The low analyte concentration range used for KD measurements here is due to sample limitations. Sensorgram traces with the model fit overlaid on the data are shown in Fig. 4d Corresponding author(s): Richard Longnecker
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Experimental design 1. Sample size
Describe how sample size was determined. Experiments were repeated three times.
Data exclusions
Describe any data exclusions. No data were excluded
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For transfections and infections, the WT and KO cells or different mutants were allocated in different sequence of plates
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
When collecting the data, investigators were blinded to the group. Because samples were marked as numbers, only after checking the transfection sheet, the group allocation were known.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
